E Point Perfect
Law \ Legal

Alzheimer’s Drug From Eisai, Biogen Gets FDA Accelerated Approval


Late last week, the U.S. Food and Drug Administration gave accelerated approval to the Alzheimer’s drug lecanemab, developed by Eisai Co. and Biogen Inc. The drug will be sold under the brand Leqembi and will run about $26,500 for a…


Source link

Related posts

Message Sent! California Attorney General Announces $1.2 Million CCPA Settlement with Retailer and Its Focus on the Sale of Customer Information

American Cannabis Policy Is the Definition of Insanity

No Limits: Board Finds Hotel Improperly Limited Bargaining Subjects

Inflation Reduction Act Imposes Prescription Drug Pricing Reforms

Judge Mesiwala nominated for 3d Dist!

An Interesting Commentary on the State of the Fiduciary Liability Insurance Market